Supernus Announces Fourth Quarter and Full Year 2014 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Supernus Pharmaceuticals (SUPN) PT Raised to $16 at Piper Jaffray Post Q4
March 12, 2015 7:21 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $16.00 (from $14.00) following Q4 results, noting continued strength for the epilepsy franchise.
Amsellem commented, "Supernus reported non-GAAP EPS of $0.08 on revenues of $31M, well... More
Supernus Pharma (SUPN) Tops Q4 EPS by 3c
March 10, 2015 5:01 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q4 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $24.4 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
... More